

Stephen M Ansell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1297974/publications.pdf>

Version: 2024-02-01

398
papers

9,478
citations

61857

43
h-index

48187

88
g-index

399
all docs

399
docs citations

399
times ranked

9939
citing authors

#	ARTICLE	IF	CITATIONS
1	High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL). <i>Leukemia</i> , 2022, 36, 165-176.	3.3	22
2	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.2	2
3	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
4	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.3	27
5	Current salvage therapies in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1267-1280.	0.6	5
6	Chronic lymphocytic leukemia (CLL) with Reedâ€“Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022, 12, 18.	2.8	9
7	Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma. <i>Frontiers in Genetics</i> , 2022, 13, 826594.	1.1	6
8	Longâ€“term outcome of immunologic autograft engineering. <i>EJHaem</i> , 2022, 3, 488-491.	0.4	3
9	Peak absolute lymphocyte count after <scp>CARâ€“T</scp> infusion predicts clinical response in aggressive lymphoma. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	2
10	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. <i>Journal of Hematology and Oncology</i> , 2022, 15, 36.	6.9	17
11	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	2.8	6
12	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.2	2
13	MLL1 inhibition reduces IgM levels in WaldenstrÃ¶m macroglobulinemia. <i>Leukemia Research</i> , 2022, 116, 106841.	0.4	2
14	Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, , 1-8.	0.6	0
15	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 473-482.	0.6	20
16	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
17	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	1.4	0
18	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for WaldenstrÃ¶m macroglobulinemia (WM): An international collaborative study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7566-7566.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Combined modality therapy for early-stage Hodgkin lymphoma in the PET era: A real-world study.. Journal of Clinical Oncology, 2022, 40, e19532-e19532.	0.8	0
20	In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART).. Journal of Clinical Oncology, 2022, 40, 7556-7556.	0.8	2
21	PJP pneumonia in brentuximab vedotin recipients.. Journal of Clinical Oncology, 2022, 40, e19533-e19533.	0.8	1
22	A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).. Journal of Clinical Oncology, 2022, 40, TPS7586-TPS7586.	0.8	0
23	Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).. Journal of Clinical Oncology, 2022, 40, LBA7564-LBA7564.	0.8	2
24	Insurance-based disparities in Waldenström Macroglobulinemia: An NCDB analysis.. Journal of Clinical Oncology, 2022, 40, e19562-e19562.	0.8	0
25	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. New England Journal of Medicine, 2022, 387, 310-320.	13.9	98
26	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	3.3	28
27	A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia, 2021, 35, 777-786.	3.3	78
28	Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. Leukemia and Lymphoma, 2021, 62, 247-251.	0.6	8
29	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	1.2	8
30	Treatment facility volume and patient outcomes in Waldenström macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	0.6	3
31	Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clinical Cancer Research, 2021, 27, 2190-2199.	3.2	110
32	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer Journal, 2021, 11, 8.	2.8	9
33	Checkpoint Blockade in Lymphoma. Journal of Clinical Oncology, 2021, 39, 525-533.	0.8	10
34	PD-1 Blockade in Classic Hodgkin Lymphoma. JCO Oncology Practice, 2021, 17, 72-73.	1.4	7
35	Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond. Leukemia and Lymphoma, 2021, 62, 1795-1804.	0.6	3
36	Novel Therapies in the Treatment of Hodgkin Lymphoma. Current Treatment Options in Oncology, 2021, 22, 42.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
38	Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. <i>Blood Cancer Journal</i> , 2021, 11, 65.	2.8	3
39	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	1.1	3
40	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 8049-8049.	0.8	1
41	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, e19501-e19501.	0.8	0
42	Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 7558-7558.	0.8	0
43	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. <i>Journal of Clinical Oncology</i> , 2021, 39, e19547-e19547.	0.8	2
44	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 7542-7542.	0.8	1
45	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. <i>Journal of Clinical Oncology</i> , 2021, 39, 7530-7530.	0.8	1
46	Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 7554-7554.	0.8	7
47	Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 7555-7555.	0.8	1
48	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 7522-7522.	0.8	3
49	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1641-1649.	0.8	16
50	Outcomes in mantle cell lymphoma with central nervous system involvement. <i>Journal of Clinical Oncology</i> , 2021, 39, e19527-e19527.	0.8	4
51	Diffuse large B-cell lymphoma with leukemic involvement. <i>Journal of Clinical Oncology</i> , 2021, 39, e19552-e19552.	0.8	0
52	The impact of body weight and body mass index on outcomes of diffuse large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Journal of Clinical Oncology</i> , 2021, 39, e19554-e19554.	0.8	0
53	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
54	CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges. <i>Annals of Translational Medicine</i> , 2021, 9, 1036-1036.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	2.2	83
56	CD5+ diffuse large B-cell lymphoma: a narrative review. <i>Leukemia and Lymphoma</i> , 2021, 62, 3078-3086.	0.6	14
57	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	2.8	4
58	Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive Non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2021, 96, E386-E389.	2.0	4
59	The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood Cancer Journal</i> , 2021, 11, 124.	2.8	9
60	The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy. <i>American Journal of Hematology</i> , 2021, 96, E399-E402.	2.0	14
61	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. <i>Hematological Oncology</i> , 2021, 39, 658-663.	0.8	8
62	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	1.2	12
63	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. <i>HemaSphere</i> , 2021, 5, e640.	1.2	7
64	Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B-cell lymphoma patients treated with axicabtagene ciloleucel. <i>American Journal of Hematology</i> , 2021, 96, E427-E430.	2.0	7
65	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. <i>Blood Cancer Journal</i> , 2021, 11, 160.	2.8	3
66	Infused Autograft Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched Case-Control Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 769.e1-769.e8.	0.6	3
67	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenström Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021, 2, 600-615.	2.6	15
68	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
69	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
70	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. <i>Transplantation</i> , 2021, 105, 1615-1624.	0.5	0
71	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. <i>Blood</i> , 2021, 138, 1327-1327.	0.6	0
72	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	0.6	1

#	ARTICLE	IF	CITATIONS
73	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN γ -NIS). Blood, 2021, 138, 1333-1333.	0.6	0
74	T-Cell Phenotype Varies in Distinct Tumor Microenvironments and CD57 + T FH Cells Are Associated with Disease Progression and Inferior Survival in Follicular Lymphoma. Blood, 2021, 138, 3522-3522.	0.6	0
75	Peak Absolute Lymphocyte Count Post CAR-T Is Associated with Clinical Response and Survival Outcome in Aggressive Lymphoma. Blood, 2021, 138, 3856-3856.	0.6	1
76	Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience. Blood, 2021, 138, 3842-3842.	0.6	1
77	Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 2021, 138, 2448-2448.	0.6	6
78	Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0383.2021.	1.1	1
79	Central Nervous System Involvement By Mantle Cell Lymphoma. Blood, 2021, 138, 2426-2426.	0.6	1
80	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. Blood, 2021, 138, 1750-1750.	0.6	2
81	Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucel CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity. Blood, 2021, 138, 2518-2518.	0.6	3
82	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. Blood, 2021, 138, 1373-1373.	0.6	2
83	Improvement in Outcomes of Autologous Stem Cell Transplant in Patients with Lymphoma Older Than 70 Years: The Significance of Age in 2020s?. Blood, 2021, 138, 2908-2908.	0.6	2
84	Response to Bridging Therapy As a Predictor of Outcomes for Chimeric Antigen Receptor Therapy in Large B-Cell Lymphoma. Blood, 2021, 138, 3841-3841.	0.6	0
85	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. Blood, 2021, 138, 1452-1452.	0.6	0
86	Vaccine Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy. Blood, 2021, 138, 3857-3857.	0.6	1
87	Immunologic Autograft Engineering: 13 Years Follow-up. Blood, 2021, 138, 3936-3936.	0.6	1
88	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. Blood, 2021, 138, 2508-2508.	0.6	0
89	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. Blood, 2021, 138, 568-568.	0.6	4
90	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. Blood, 2021, 138, 808-808.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	0.6	3
92	Autograft-Absolute Lymphocyte Count Infusion Predicts Survival in Double/Triple Hit Lymphomas Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 1836-1836.	0.6	1
93	Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. <i>Leukemia and Lymphoma</i> , 2020, 61, 298-308.	0.6	15
94	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	0.6	9
95	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	2.9	22
96	Association between facility volume and mortality of patients with classic Hodgkin lymphoma. <i>Cancer</i> , 2020, 126, 757-764.	2.0	5
97	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41
98	Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1063-1074.	0.6	6
99	Activation-induced T-cell exhaustion: too much of a good thing?. <i>Leukemia and Lymphoma</i> , 2020, 61, 255-256.	0.6	0
100	Impact of MYD88^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
101	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020, 34, 1373-1382.	3.3	40
102	Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2217-2222.	2.0	7
103	Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy. <i>Brain Communications</i> , 2020, 2, fcaa050.	1.5	6
104	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
105	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. <i>Clinical Cancer Research</i> , 2020, 26, 5759-5771.	3.2	5
106	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	2.8	18
107	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020, 136, 2401-2409.	0.6	92
108	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	0.6	14

#	ARTICLE	IF	CITATIONS
109	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , 2020, 7, e660-e670.	2.2	86
110	Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	13
111	Safety and activity of varilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 1917-1926.	2.5	51
112	Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. <i>Cancer Treatment Reviews</i> , 2020, 88, 102042.	3.4	20
113	Immunomodulators in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 28.	1.3	4
114	The immune landscape and response to immune checkpoint blockade therapy in lymphoma. <i>Blood</i> , 2020, 135, 523-533.	0.6	134
115	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
116	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.	0.6	3
117	Odronektamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy. <i>Blood</i> , 2020, 136, 42-43.	0.6	87
118	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Blood</i> , 2020, 136, 26-28.	0.6	5
119	Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolbenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 21-23.	0.6	16
120	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
121	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2020, 136, 29-30.	0.6	3
122	Effect of antibiotic use prior to or concurrent with immune checkpoint inhibitors on outcomes in patients with Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8030-8030.	0.8	0
123	Fundamentals of immunology for understanding immunotherapy for lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 585-589.	0.9	1
124	Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 41-43.	0.6	5
125	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. <i>Blood Advances</i> , 2020, 4, 5089-5092.	2.5	5
126	Pre-Existing T Cell Subsets Determine Anti-PD1 Blockade Response in Richter's Transformation. <i>Blood</i> , 2020, 136, 42-43.	0.6	0

#	ARTICLE	IF	CITATIONS
127	High-Dimensional and Single-Cell Transcriptome Analysis of AITL Tumor Microenvironment Reveals Gross Expansion of Novel Dysfunctional CD8+ T Cell Populations, Global Shift in B Cell Phenotypes. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
128	Response to Bridging Therapy (BT) before CART-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 30-30.	0.6	1
129	The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucl. <i>Blood</i> , 2020, 136, 23-25.	0.6	0
130	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
131	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 10-12.	0.6	0
132	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020, 136, 3-4.	0.6	1
133	Hypomagnesemia Is Associated with an Increased Risk of Failure in Patients Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 21-21.	0.6	0
134	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2020, 136, 42-43.	0.6	0
135	Infused Autograft-Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B-Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched-Control Study. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
136	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
137	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
138	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	0
139	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
140	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	0.6	26
141	SIRP α expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 84.	2.8	35
142	Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma. <i>Lancet Haematology</i> , 2019, 6, e2-e3.	2.2	8
143	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
144	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37

#	ARTICLE	IF	CITATIONS
145	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 820-828.	1.2	12
146	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. <i>Blood</i> , 2019, 133, 2776-2789.	0.6	55
147	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 786-793.	2.0	15
148	Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis. <i>Leukemia Research</i> , 2019, 81, 1-9.	0.4	12
149	Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2019, 60, 2599-2601.	0.6	0
150	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
151	The Highs and Lows of Immune-Checkpoint Blockade in Lymphoma. <i>Cancer Immunology Research</i> , 2019, 7, 696-700.	1.6	14
152	Two types of amyloidosis presenting in a single patient: a case series. <i>Blood Cancer Journal</i> , 2019, 9, 30.	2.8	48
153	Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , 2019, 186, e24-e27.	1.2	15
154	Immunotherapy in Hodgkin Lymphoma: The Road Ahead. <i>Trends in Immunology</i> , 2019, 40, 380-386.	2.9	19
155	Immunotransplant: Preventing Unintended Consequences. <i>Cancer Discovery</i> , 2019, 9, 1487-1489.	7.7	2
156	CAR T-cells: Driving in the Fast Lane. <i>HemaSphere</i> , 2019, 3, e209.	1.2	1
157	Tumor Microenvironment in T-Cell Lymphomas. <i>Cancer Treatment and Research</i> , 2019, 176, 69-82.	0.2	10
158	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 1718-1726.	3.2	26
159	Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?. <i>Leukemia and Lymphoma</i> , 2019, 60, 1114-1115.	0.6	1
160	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
161	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305.	0.6	69
162	Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides. <i>Investigational New Drugs</i> , 2019, 37, 9-16.	1.2	5

#	ARTICLE	IF	CITATIONS
163	Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era. Blood, 2019, 134, 4038-4038.	0.6	1
164	Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life. Blood, 2019, 134, 794-794.	0.6	14
165	Mass Cytometry Identifies a Novel Signature for Myeloid-Derived Suppressor-Cells in Waldenstrom's Macroglobulinemia. Blood, 2019, 134, 3976-3976.	0.6	1
166	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. Blood, 2019, 134, 775-775.	0.6	5
167	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2019, 134, 467-467.	0.6	29
168	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood, 2019, 134, 121-121.	0.6	7
169	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucef Therapy for Lymphoma. Blood, 2019, 134, 4106-4106.	0.6	6
170	Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study. Blood, 2019, 134, 4090-4090.	0.6	1
171	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). Blood, 2019, 134, 1591-1591.	0.6	3
172	Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma. Blood, 2019, 134, 1517-1517.	0.6	7
173	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucef (axi-cel). Blood, 2019, 134, 5343-5343.	0.6	1
174	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	0.6	0
175	Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 2896-2896.	0.6	2
176	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. Blood, 2019, 134, 2774-2774.	0.6	0
177	Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. Blood, 2019, 134, 2764-2764.	0.6	0
178	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 919-919.	0.6	0
179	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. Blood, 2019, 134, 923-923.	0.6	0
180	Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma. Blood, 2019, 134, 410-410.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	0.6	0
182	Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma. <i>Blood</i> , 2019, 134, 2790-2790.	0.6	0
183	Glutathione Metabolism Contributes to the Pathobiology of Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2019, 134, 3971-3971.	0.6	0
184	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. <i>Blood</i> , 2019, 134, 4026-4026.	0.6	0
185	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5293-5293.	0.6	2
186	MLL1 Modulates IgM and Inflammatory Cytokines in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2019, 134, 3966-3966.	0.6	0
187	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology</i> , The, 2018, 19, 549-561.	5.1	165
188	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	0.6	130
189	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
190	Primary central nervous system vasculitis associated with lymphoma. <i>Neurology</i> , 2018, 90, e847-e855.	1.5	22
191	Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia—Reply. <i>JAMA Oncology</i> , 2018, 4, 745.	3.4	1
192	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2128-2134.	0.6	5
193	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 26.	2.8	92
194	Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 221-224.	0.6	12
195	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	1.2	5
196	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	13.9	564
197	Acalabrutinib in mantle cell lymphoma. <i>Lancet</i> , The, 2018, 391, 633-634.	6.3	7
198	Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 249-253.	1.0	4

#	ARTICLE	IF	CITATIONS
199	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	0.6	97
200	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 97.	2.8	36
201	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	1.2	20
202	Defining Lymphoplasmacytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 168-176.	0.4	5
203	The Bone Marrow Microenvironment in Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 777-786.	0.9	6
204	Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 57.	6.9	19
205	Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2018, 183, 196-211.	1.2	16
206	Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. <i>Clinical Cancer Research</i> , 2018, 24, 6408-6420.	3.2	15
207	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	1.7	52
208	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 664-672.e2.	0.2	6
209	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. <i>Blood</i> , 2018, 132, 2247-2247.	0.6	2
210	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2018, 132, 454-454.	0.6	1
211	Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes. <i>Blood</i> , 2018, 132, 1690-1690.	0.6	12
212	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2018, 132, 456-456.	0.6	4
213	Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results. <i>Blood</i> , 2018, 132, 2899-2899.	0.6	10
214	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018, 132, 4204-4204.	0.6	1
215	Tigit Expression Defines a Subset of Activated Treg Cells with Prognostic Relevance in Follicular Lymphoma. <i>Blood</i> , 2018, 132, 1590-1590.	0.6	6
216	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). <i>Blood</i> , 2018, 132, 679-679.	0.6	13

#	ARTICLE	IF	CITATIONS
217	A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. <i>Blood</i> , 2018, 132, 1620-1620.	0.6	12
218	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). <i>Blood</i> , 2018, 132, 623-623.	0.6	1
219	Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7539-7539.	0.8	5
220	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622.	0.6	1
221	Ibrutinib for the Treatment of Bing-Neel Syndrome. <i>Blood</i> , 2018, 132, 1609-1609.	0.6	2
222	Depth of Response in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	0.6	2
223	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018, 132, 1606-1606.	0.6	1
224	PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. <i>Blood</i> , 2018, 132, 586-586.	0.6	2
225	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). <i>Blood</i> , 2018, 132, 4138-4138.	0.6	0
226	Prevalence and Regulation of Effector CD8+ T Cell Subsets in B-Cell NHL. <i>Blood</i> , 2018, 132, 4134-4134.	0.6	0
227	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
228	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2018, 132, 2979-2979.	0.6	0
229	Prognosis of Patients with Waldenstrom Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018, 132, 4152-4152.	0.6	1
230	Infusion of NKp30/KIR2DL2 Natural Killer Cell Ratio and Survival Post-Autologous Stem Cell Transplantation in Lymphomas. <i>Blood</i> , 2018, 132, 3430-3430.	0.6	0
231	FCGR3A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	0.8	9
232	Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. <i>Human Pathology</i> , 2017, 64, 19-27.	1.1	41
233	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 448-453.	2.0	26
234	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 427-433.	1.2	15

#	ARTICLE	IF	CITATIONS
235	Peripheral T-cell lymphomas: very little good, mainly the bad and the ugly. <i>Leukemia and Lymphoma</i> , 2017, 58, 2273-2274.	0.6	0
236	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017, 129, 3037-3039.	0.6	68
237	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
238	Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 1375-1377.	0.6	37
239	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
240	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
241	Nivolumab in the Treatment of Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1623-1626.	3.2	45
242	Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma. <i>HemaSphere</i> , 2017, 1, e7.	1.2	1
243	Advances in the understanding of IgM monoclonal gammopathy of undetermined significance. <i>F1000Research</i> , 2017, 6, 2142.	0.8	11
244	Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 649-649.	0.6	7
245	Recent advances in the management of Hodgkin lymphoma. <i>F1000Research</i> , 2016, 5, 768.	0.8	4
246	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. <i>British Journal of Haematology</i> , 2016, 172, 535-544.	1.2	71
247	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
248	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1321-1328.	0.6	161
249	Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 179-186.	0.7	12
250	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
251	Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond. <i>American Journal of Hematology</i> , 2016, 91, 109-112.	2.0	20
252	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016, 127, 2936-2938.	0.6	17

#	ARTICLE	IF	CITATIONS
253	Hodgkin lymphoma: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 434-442.	2.0	84
254	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. <i>Current Treatment Options in Oncology</i> , 2016, 17, 16.	1.3	12
255	Immune checkpoint blockade in lymphoid malignancies. <i>FEBS Journal</i> , 2016, 283, 2233-2244.	2.2	18
256	Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1017-1023.	2.0	20
257	Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 5-12.	1.1	13
258	Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2016, 128, 104-104.	0.6	14
259	Altered Expression of Immune Checkpoint Molecules Including Programmed Cell Death-1 (PD-1) and Its Ligands PD-L1/PD-L2 in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1772-1772.	0.6	1
260	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016, 128, 4392-4392.	0.6	8
261	Sustained Natural Killer Cell Recovery Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation Predicts Survival in Non-Hodgkin's Lymphoma. <i>Blood</i> , 2016, 128, 4641-4641.	0.6	3
262	Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node. <i>PLoS ONE</i> , 2016, 11, e0155347.	1.1	20
263	Signal-Regulatory Protein-1 (SIRP-1) Expression Delineates Distinct Subsets in Monocytes/Macrophages in Normal Tissue and in B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 2515-2515.	0.6	0
264	Inhibiting IL-2 Signaling and the Regulatory T-Cell Pathway Using Computationally Designed Novel Peptides. <i>Blood</i> , 2016, 128, 3875-3875.	0.6	0
265	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935.	0.6	0
266	Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 80.	6.9	7
267	Targeting immune checkpoints in lymphoma. <i>Current Opinion in Hematology</i> , 2015, 22, 337-342.	1.2	38
268	Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma. <i>Journal of Blood Medicine</i> , 2015, 6, 45.	0.7	8
269	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.	0.6	92
270	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenstrom Macroglobulinemia. <i>Clinical Cancer Research</i> , 2015, 21, 2538-2545.	3.2	19

#	ARTICLE	IF	CITATIONS
271	Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma. Expert Opinion on Orphan Drugs, 2015, 3, 921-932.	0.5	0
272	Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic Proceedings, 2015, 90, 1574-1583.	1.4	120
273	Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Expert Review of Anticancer Therapy, 2015, 15, 1143-1156.	1.1	5
274	Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic Proceedings, 2015, 90, 1152-1163.	1.4	115
275	Multiparametric Analysis of Intra-Tumoral T-Cells in Hodgkin's Lymphoma Using Mass Cytometry (CyTOF). Blood, 2015, 126, 1438-1438.	0.6	1
276	Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia. Blood, 2015, 126, 1540-1540.	0.6	8
277	The Exhausted Intratumoral T Cell Population in B-Cell Non-Hodgkin Lymphoma Is Defined By LAG-3, PD-1 and tim-3 Expression. Blood, 2015, 126, 2661-2661.	0.6	7
278	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. Blood, 2015, 126, 2683-2683.	0.6	6
279	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. Blood, 2015, 126, 3730-3730.	0.6	0
280	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenström Macroglobulinemia. Blood, 2015, 126, 703-703.	0.6	4
281	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. Blood, 2015, 126, 2490-2490.	0.6	0
282	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. Blood, 2015, 126, 4993-4993.	0.6	0
283	<sc>AT</sc>â€101 downregulates <sc>BCL</sc>2 and <sc>MCL</sc>1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and <sc>W</sc>aldenström macroglobulinaemia. British Journal of Haematology, 2014, 164, 352-365.	1.2	30
284	Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma. Clinical Cancer Research, 2014, 20, 2862-2872.	3.2	86
285	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 87-97.	0.9	32
286	Induction Therapy for Advanced-stage Hodgkin Lymphoma. Hematology/Oncology Clinics of North America, 2014, 28, 75-86.	0.9	3
287	Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 1804-1812.	2.0	22
288	Hodgkin lymphoma: 2014 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2014, 89, 771-779.	2.0	28

#	ARTICLE	IF	CITATIONS
289	Follicular lymphoma: watch and wait is watch and worry. <i>Lancet Oncology</i> , The, 2014, 15, 368-369.	5.1	10
290	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	0.6	401
291	Brentuximab vedotin. <i>Blood</i> , 2014, 124, 3197-3200.	0.6	81
292	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. <i>Lancet Oncology</i> , The, 2013, 14, 1348-1356.	5.1	251
293	Inhibition Of The Deubiquitinating Enzymes UCHL5 and USP14 Is Lethal To Waldenström's Macroglobulinemia Cells. <i>Blood</i> , 2013, 122, 1823-1823.	0.6	2
294	A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial. <i>Blood</i> , 2013, 122, 3044-3044.	0.6	2
295	PD-1 Expression Defines Two Distinct T-Cell Subpopulations That Differentially Impact Patient Outcomes In Follicular Lymphoma. <i>Blood</i> , 2013, 122, 366-366.	0.6	3
296	Interactions Between PD-1 and PD-L1 and PD-L2 Promote Malignant B-Cell Growth in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2013, 122, 4334-4334.	0.6	5
297	Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 4382-4382.	0.6	19
298	Cellular Composition of the Tumor Microenvironment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e91-e97.	1.8	53
299	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. <i>Blood</i> , 2013, 122, 499-499.	0.6	2
300	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	0.6	1
301	Heterogeneous Bcl-2 Family Expression In Waldenström Macroglobulinemia Determines Response To Inducers Of Intrinsic Apoptosis. <i>Blood</i> , 2013, 122, 4287-4287.	0.6	0
302	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. <i>Blood</i> , 2013, 122, 1774-1774.	0.6	0
303	Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs. <i>Blood</i> , 2013, 122, 1928-1928.	0.6	0
304	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. <i>Blood</i> , 2013, 122, 626-626.	0.6	0
305	Activation Of TAK1 By MYD88 L265P Drives Malignant B Cell Growth In Non-Hodgkin Lymphomas. <i>Blood</i> , 2013, 122, 245-245.	0.6	1
306	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. <i>Blood</i> , 2013, 122, 841-841.	0.6	0

#	ARTICLE	IF	CITATIONS
307	The Deubiquitinating Enzymes Of The 19S Proteasome Offer Novel Therapeutic Opportunity In Bortezomib Resistant Waldenström's Macroglobulinemia. <i>Blood</i> , 2013, 122, 4426-4426.	0.6	0
308	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4306-4306.	0.6	0
309	Copy Number Abnormalities Of The Interferon Regulatory Factor-4 (IRF4) Gene Are Associated With IRF4/MUM1 Expression In Peripheral T-Cell Lymphomas. <i>Blood</i> , 2013, 122, 3016-3016.	0.6	0
310	t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. <i>Blood</i> , 2012, 120, 3949-3957.	0.6	48
311	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.	0.8	1,332
312	Beyond targeting malignant B cells. <i>Lancet Oncology</i> , The, 2012, 13, 657-658.	5.1	0
313	Hodgkin lymphoma: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012, 87, 1096-1103.	2.0	34
314	Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy. <i>Mayo Clinic Proceedings</i> , 2012, 87, 571-580.	1.4	56
315	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 865-869.	2.0	37
316	MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.. <i>Blood</i> , 2012, 120, 2699-2699.	0.6	3
317	Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 3689-3689.	0.6	4
318	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. <i>Blood</i> , 2012, 120, 3701-3701.	0.6	7
319	Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study. <i>Blood</i> , 2012, 120, 689-689.	0.6	8
320	Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 798-798.	0.6	9
321	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. <i>Blood</i> , 2012, 120, 1525-1525.	0.6	0
322	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL). <i>Blood</i> , 2012, 120, 1527-1527.	0.6	0
323	The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2700-2700.	0.6	31
324	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 600-600.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 684-684.	0.6	0
326	Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia. <i>Blood</i> , 2012, 120, 3723-3723.	0.6	0
327	Biologic Activity of STAT5A and STAT5B in Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2012, 120, 2688-2688.	0.6	0
328	LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.. <i>Blood</i> , 2012, 120, 2741-2741.	0.6	0
329	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	0.6	0
330	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	0.6	0
331	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).. <i>Blood</i> , 2012, 120, 2634-2634.	0.6	0
332	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. <i>Blood</i> , 2012, 120, 3637-3637.	0.6	0
333	IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2012, 120, 1554-1554.	0.6	0
334	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , 2012, 120, 2702-2702.	0.6	0
335	Brentuximab vedotin: delivering an antimetabolic drug to activated lymphoma cells. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 99-105.	1.9	35
336	Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. <i>Lancet Oncology</i> , The, 2011, 12, 361-368.	5.1	151
337	Hodgkin lymphoma: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 851-858.	2.0	7
338	Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy. <i>Blood</i> , 2011, 118, 1640-1640.	0.6	1
339	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 3095-3095.	0.6	1
340	ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature. <i>Blood</i> , 2011, 118, 88-88.	0.6	3
341	Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 955-955.	0.6	28
342	TGF- β 2 Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011, 118, 1586-1586.	0.6	1

#	ARTICLE	IF	CITATIONS
343	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. <i>Blood</i> , 2011, 118, 429-429.	0.6	1
344	IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 770-770.	0.6	0
345	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. <i>Blood</i> , 2011, 118, 3652-3652.	0.6	0
346	A Lymphoma-Associated Mutation in BAFF-R Drives Constitutive PI3K Signaling and Increased Expression of Pro-Survival Genes. <i>Blood</i> , 2011, 118, 2642-2642.	0.6	0
347	UCH-L1 Is a Novel Regulator of mTOR Signaling That May Predict a Poor Response to mTOR Inhibition in Patients with B-Cell Lymphoma,. <i>Blood</i> , 2011, 118, 3691-3691.	0.6	0
348	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. <i>Blood</i> , 2011, 118, 1926-1926.	0.6	0
349	Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience. <i>Blood</i> , 2011, 118, 1572-1572.	0.6	0
350	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,. <i>Blood</i> , 2011, 118, 3642-3642.	0.6	0
351	The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma. <i>Blood</i> , 2011, 118, 85-85.	0.6	1
352	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. <i>Blood</i> , 2011, 118, 2682-2682.	0.6	0
353	Author reply: Flows and flaws in primary CNS lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-1.	12.5	0
354	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. <i>Mayo Clinic Proceedings</i> , 2010, 85, 824-833.	1.4	152
355	Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.. <i>Blood</i> , 2010, 116, 2802-2802.	0.6	2
356	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , 2010, 116, 287-287.	0.6	5
357	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. <i>Blood</i> , 2010, 116, 3557-3557.	0.6	1
358	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience. <i>Blood</i> , 2010, 116, 4168-4168.	0.6	5
359	A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development. <i>Blood</i> , 2010, 116, 1999-1999.	0.6	0
360	The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 3088-3088.	0.6	0

#	ARTICLE	IF	CITATIONS
361	GATA-3 or T-Bet Expression In PTCL-U Identify High-Risk Patients with Poor Outcomes and Distinct Clinical Characteristics Suggesting Their Derivation From Specific Subsets of T Helper Cells. <i>Blood</i> , 2010, 116, 4125-4125.	0.6	0
362	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2010, 116, 991-991.	0.6	1
363	Massively Parallel Mate Pair DNA Library Sequencing for Translocation Discovery: Recurrent t(6;7)(p25.3;q32.3) Translocations In ALK-Negative Anaplastic Large Cell Lymphomas. <i>Blood</i> , 2010, 116, 633-633.	0.6	1
364	Clinicopathological and Cytogenetic Comparison of Patients with Acute T Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2010, 116, 2705-2705.	0.6	0
365	Role of Heparin In Anemia of Waldenström Macroglobulinemia. <i>Blood</i> , 2010, 116, 4984-4984.	0.6	0
366	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. <i>Blood</i> , 2010, 116, 140-140.	0.6	10
367	GLI2, An Effector of the Hedgehog Pathway, Is a Novel Regulator of IL6 Oncogenic Function In the Tumor Microenvironment. <i>Blood</i> , 2010, 116, 613-613.	0.6	0
368	Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival. <i>Blood</i> , 2010, 116, 4136-4136.	0.6	0
369	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. <i>Blood</i> , 2010, 116, 468-468.	0.6	0
370	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. <i>Blood</i> , 2010, 116, 3115-3115.	0.6	0
371	Outcomes In the Pre-Rituximab and Post-Rituximab Eras In Post-Transplantation Lymphoproliferative Disorders (PTLD) In Adult Solid Organ Transplant Recipients. <i>Blood</i> , 2010, 116, 2859-2859.	0.6	3
372	Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2010, 116, 2862-2862.	0.6	0
373	A Novel IL-12-TIM-3 Pathway Induces T Cell Exhaustion and Predicts Reduced Survival In Patients with Follicular B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 143-143.	0.6	1
374	Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 6446-6453.	3.2	297
375	Serum BlyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2009, 84, 71-73.	2.0	15
376	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2009, 114, 925-925.	0.6	1
377	Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 1105-1110.	3.2	37
378	Absolute Lymphocyte Count at the Time of Relapse Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 1763-1763.	0.6	1

#	ARTICLE	IF	CITATIONS
379	Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 603-603.	0.6	4
380	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 121-121.	0.6	31
381	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. <i>Blood</i> , 2007, 110, 2995-2995.	0.6	0
382	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 124-124.	0.6	2
383	Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients. <i>Clinical Cancer Research</i> , 2006, 12, 6056-6063.	3.2	52
384	The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism.. <i>Blood</i> , 2006, 108, 234-234.	0.6	2
385	Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006, 108, 2729-2729.	0.6	5
386	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. <i>Blood</i> , 2006, 108, 530-530.	0.6	6
387	Improved Survival in Patients with Peripheral T Cell Lymphoma, Unspecified Following High-Dose Therapy and Stem Cell Transplantation: A Retrospective Review of a Single Institution's Experience.. <i>Blood</i> , 2006, 108, 3062-3062.	0.6	0
388	Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.. <i>Blood</i> , 2005, 106, 2411-2411.	0.6	3
389	Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.. <i>Blood</i> , 2005, 106, 938-938.	0.6	8
390	Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma.. <i>Blood</i> , 2005, 106, 4698-4698.	0.6	0
391	Topotecan in Patients With Advanced Neuroendocrine Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 232-235.	0.6	32
392	Lack of Increased Clinical Efficacy When Interleukin-12 Is Added to Rituximab in B-Cell Lymphoma Patients Is Related to Inadequate Delivery of the Cytokine to the Sites of Lymphoma.. <i>Blood</i> , 2004, 104, 1397-1397.	0.6	0
393	B-Lymphocyte Stimulator (BLyS) Is Highly Expressed in Waldenström's Macroglobulinemia.. <i>Blood</i> , 2004, 104, 2291-2291.	0.6	1
394	Antibody therapy for non-Hodgkin's lymphoma. <i>Current Opinion in Molecular Therapeutics</i> , 2004, 6, 175-81.	2.8	0
395	Adding Cytokines to Monoclonal Antibody Therapy: Does the Concurrent Administration of Interleukin-12 Add to the Efficacy of Rituximab in B-cell Non-Hodgkin Lymphoma?. <i>Leukemia and Lymphoma</i> , 2003, 44, 1309-1315.	0.6	15
396	Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2002, 99, 67-74.	0.6	149

#	ARTICLE	IF	CITATIONS
397	Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis. <i>Leukemia and Lymphoma</i> , 2001, 42, 1329-1337.	0.6	28
398	Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis. <i>JCO Oncology Practice</i> , 0, , .	1.4	0